CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

NCT06690775 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

230

Enrollment

INDUSTRY

Sponsor class

Conditions

Epithelial Ovarian Cancer
Primary Peritoneal
Fallopian Tube Cancer
Endometrioid Ovarian Cancer

Interventions

DRUG: TORL-1-23
DRUG: TORL-1-23
DRUG: TORL-1-23
DRUG: Pegfilgrastim (drug)

Sponsor

TORL Biotherapeutics, LLC

Collaborators

[object Object]